Cutaneous gamma/delta T‐cell lymphoma

Koch, Richard; Jaffe, Elaine S.; Mensing, Christian; Zeis, Matthias; Schmitz, Norbert; Sander, Christian

doi:10.1111/j.1610-0387.2009.07209.x

Cited by 23 publications

(25 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Because CGD-TCL is considered as an aggressive lymphoma with a poor prognosis, the diagnosis of this lymphoma usually implies the need for an aggressive therapeutic approach with multiagent chemotherapy, eventually in combination with alemtuzumab and followed by stem cell transplantation. 22 In contrast, phototherapy (psoralen-UV-A or UV-B narrowband) combined with topical corticosteroids or retinoids are the first-line strategy for MF in patch/plaque stage. 23,24 The situation becomes even more complex by the increasing insight into the wide prognostic spectrum even within the individual CTCL entities.…”

Section: Discussionmentioning

confidence: 99%

Two Cases of Primary Cutaneous Lymphoma With a γ/δ+ Phenotype and an Indolent Course

Kempf¹,

Kazakov

Scheidegger

et al. 2014

The American Journal of Dermatopathology

View full text Add to dashboard Cite

Cutaneous [gamma]/[delta]+ T-cell lymphoma (CGD-TCL) is a rare but aggressive lymphoma associated with a poor prognosis in most patients. The clinicopathological spectrum is variable including predominantly epidermotropic infiltrates manifesting with patches and plaques or tumors with dermal and/or subcutaneous infiltrates. The diagnosis of CGD-TCL requires the demonstration of a [gamma]/[delta]+ phenotype by immunohistochemistry. We report 2 patients with epidermotropic cutaneous T-cell lymphomas displaying a [gamma]/[delta]+ phenotype, but exhibiting an indolent course. In one patient, the clinical presentation was similar to mycosis fungoides in patch and plaque stage, but recurrent blister formation within the lesions was observed accompanied by fever and arthralgias, whereas the second patient presented with 2 localized erosive plaques on the left temple and dense epidermotropic and dermal diffuse and folliculotropic infiltrates of atypical small-to-medium-sized lymphocytes. exhibiting an indolent course. In one patient, the clinical presentation was similar to mycosis fungoides in patch and plaque stage, but recurrent blister formation within the lesions was observed accompanied by fever and arthralgias, whereas the second patient presented with 2 localized erosive plaques on the left temple and dense epidermotropic and dermal diffuse and folliculotropic infiltrates of atypical small-tomedium-sized lymphocytes. These cases corroborate the view that expression of a g/d+ phenotype in cutaneous T-cell lymphomas per se does not portend a worse prognosis and that CGD-TCL may represent a clinically and prognostically heterogeneous group.

show abstract

Section: Discussionmentioning

confidence: 99%

Two Cases of Primary Cutaneous Lymphoma With a γ/δ+ Phenotype and an Indolent Course

Kempf¹,

Kazakov

Scheidegger

et al. 2014

The American Journal of Dermatopathology

View full text Add to dashboard Cite

show abstract

“…Of the 86 cases reported, there are but a handful of patients who achieved remission and meaningful long-term survival. Among cases confirmed to be PCGD-TCL on the basis of TCR PCR, 1 long-term survivor was treated with CHOP, then interferon > and isoretinoin, then staurosporine 29 ; a second was refractory to a series of treatment including interferon >, chemotherapy, methotrexate, and asparaginase, before ultimately undergoing allogeneic stem cell transplantation, 30 and a third received electron beam therapy, retinoid therapy (etretinate), and narrow-band UVB. 33 Other favorable outcomes are also reported as case reports or small, potentially heterogeneous case series.…”

Section: The Primary Cutaneous T-cell Lymphomasmentioning

confidence: 99%

“…29 Primary cutaneous F/C TCL is an extremely aggressive disease with a poor prognosis and a median survival of 15 months (compared with several years for even advanced cases of MF/SS). 30,31 It has been treated with multiagent chemotherapy using CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) or other anthracycline-based regimens. However, it has proven to be resistant to chemotherapy in most cases.…”

Section: The Primary Cutaneous T-cell Lymphomasmentioning

confidence: 99%

Management of the Cutaneous Peripheral T-Cell Lymphomas

Choi

Lechowicz²

2012

The Cancer Journal

View full text Add to dashboard Cite

The cutaneous T-cell lymphomas are a heterogeneous collection of many biologically and clinically distinct cancers. The World Health Organization 2008 reclassification of cutaneous lymphomas delineated provisional entities that were previously classified simply as primary cutaneous peripheral T-cell lymphoma not otherwise specified. Because of the relative rarity of cases, standard treatment recommendations and algorithms are lacking. However, identification of these subtypes is important as they can have vastly different clinical outcomes. Furthermore, cytokine treatments effective in classic mycosis fungoides or Sezary syndrome not only are ineffective, but also may exacerbate certain subtypes. The aim of this review was to summarize the biological bases of the recently defined entities, reinforce the importance of acute clinical/pathologic diagnosis, and propose treatment strategies based on the available data.

show abstract

“…In most centers, doxorubicin-based chemotherapy is the preferred type of treatment, sometimes in combination with alemtuzumab or followed by an auto-stem cell transplantation for consolidation. Hematopoietic stem cell transplantation can induce a complete remission: allogenic stem cell transplantation appears to be a promising therapeutic option for aggressive and generally fatal lymphomas, like CGD-TCL [12] .…”

Section: Discussionmentioning

confidence: 99%

Two Atypical Cases of Cutaneous Gamma/Delta T-Cell Lymphomas

Caudron

Bouaziz

Battistella³

et al. 2011

Dermatology

View full text Add to dashboard Cite

Cutaneous γ/δ T-cell lymphoma (CGD-TCL) is a recent entity described in the newly revised World Health Organization-European Organization for Research and Treatment of Cancer classification of cutaneous lymphomas, and is characterized by the γ/δ T-cell receptor expression on atypical lymphocytes. Only a few cases of primary CGD-TCL have been reported, with an extremely aggressive course (median survival time of 15 months). We describe 2 atypical cases of CGD-TCL. The first case was initially misdiagnosed as an inflammatory panniculitis due to the granulomatous infiltrate on the skin biopsy specimen. Diagnosis was confirmed using δ PCR that revealed γ/δ T-cell clonal expansion. The evolution was marked by predominant γ/δ T-cell infiltrate with diffuse body fat involvement as seen on positron emission tomography-computed tomography. The second case is the first described Epstein-Barr virus (EBV)-associated CGD-TCL with a rapidly fatal evolution. CGD-TCL is also a heterogeneous entity and δ PCR and EBV-encoded RNA probe to detect an EBV latent infection may help diagnose and characterize these cutaneous lymphomas.

show abstract

Cutaneous gamma/delta T‐cell lymphoma

Cited by 23 publications

References 4 publications

Two Cases of Primary Cutaneous Lymphoma With a γ/δ+ Phenotype and an Indolent Course

Two Cases of Primary Cutaneous Lymphoma With a γ/δ+ Phenotype and an Indolent Course

Management of the Cutaneous Peripheral T-Cell Lymphomas

Two Atypical Cases of Cutaneous Gamma/Delta T-Cell Lymphomas

Contact Info

Product

Resources

About